Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2008

Zachary K Sweeney, and James P Dunn, and Yu Li, and Gabrielle Heilek, and Pete Dunten, and Todd R Elworthy, and Xiaochun Han, and Seth F Harris, and Donald R Hirschfeld, and J Heather Hogg, and Walter Huber, and Ann C Kaiser, and Denis J Kertesz, and Woongki Kim, and Taraneh Mirzadegan, and Michael G Roepel, and Y David Saito, and Tania M P C Silva, and Steven Swallow, and Jahari L Tracy, and Armando Villasenor, and Harit Vora, and Amy S Zhou, and Klaus Klumpp
Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, CA 94304, USA. zachary.sweeney@roche.com

A series of benzyl pyridazinones were evaluated as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Several members of this series showed good activity against the wild-type virus and NNRTI-resistant viruses. The binding of inhibitor 5a to HIV-RT was analyzed by surface plasmon resonance spectroscopy. Pharmacokinetic studies of 5a in rat and dog demonstrated that this compound has good oral bioavailability in animal species. The crystal structure of a complex between HIV-RT and inhibitor 4c is also described.

UI MeSH Term Description Entries
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

Zachary K Sweeney, and James P Dunn, and Yu Li, and Gabrielle Heilek, and Pete Dunten, and Todd R Elworthy, and Xiaochun Han, and Seth F Harris, and Donald R Hirschfeld, and J Heather Hogg, and Walter Huber, and Ann C Kaiser, and Denis J Kertesz, and Woongki Kim, and Taraneh Mirzadegan, and Michael G Roepel, and Y David Saito, and Tania M P C Silva, and Steven Swallow, and Jahari L Tracy, and Armando Villasenor, and Harit Vora, and Amy S Zhou, and Klaus Klumpp
August 2016, Bioorganic & medicinal chemistry letters,
Zachary K Sweeney, and James P Dunn, and Yu Li, and Gabrielle Heilek, and Pete Dunten, and Todd R Elworthy, and Xiaochun Han, and Seth F Harris, and Donald R Hirschfeld, and J Heather Hogg, and Walter Huber, and Ann C Kaiser, and Denis J Kertesz, and Woongki Kim, and Taraneh Mirzadegan, and Michael G Roepel, and Y David Saito, and Tania M P C Silva, and Steven Swallow, and Jahari L Tracy, and Armando Villasenor, and Harit Vora, and Amy S Zhou, and Klaus Klumpp
February 2006, Bioorganic & medicinal chemistry letters,
Zachary K Sweeney, and James P Dunn, and Yu Li, and Gabrielle Heilek, and Pete Dunten, and Todd R Elworthy, and Xiaochun Han, and Seth F Harris, and Donald R Hirschfeld, and J Heather Hogg, and Walter Huber, and Ann C Kaiser, and Denis J Kertesz, and Woongki Kim, and Taraneh Mirzadegan, and Michael G Roepel, and Y David Saito, and Tania M P C Silva, and Steven Swallow, and Jahari L Tracy, and Armando Villasenor, and Harit Vora, and Amy S Zhou, and Klaus Klumpp
April 2012, Bioorganic & medicinal chemistry letters,
Zachary K Sweeney, and James P Dunn, and Yu Li, and Gabrielle Heilek, and Pete Dunten, and Todd R Elworthy, and Xiaochun Han, and Seth F Harris, and Donald R Hirschfeld, and J Heather Hogg, and Walter Huber, and Ann C Kaiser, and Denis J Kertesz, and Woongki Kim, and Taraneh Mirzadegan, and Michael G Roepel, and Y David Saito, and Tania M P C Silva, and Steven Swallow, and Jahari L Tracy, and Armando Villasenor, and Harit Vora, and Amy S Zhou, and Klaus Klumpp
January 2002, Progress in medicinal chemistry,
Zachary K Sweeney, and James P Dunn, and Yu Li, and Gabrielle Heilek, and Pete Dunten, and Todd R Elworthy, and Xiaochun Han, and Seth F Harris, and Donald R Hirschfeld, and J Heather Hogg, and Walter Huber, and Ann C Kaiser, and Denis J Kertesz, and Woongki Kim, and Taraneh Mirzadegan, and Michael G Roepel, and Y David Saito, and Tania M P C Silva, and Steven Swallow, and Jahari L Tracy, and Armando Villasenor, and Harit Vora, and Amy S Zhou, and Klaus Klumpp
June 2010, ChemMedChem,
Zachary K Sweeney, and James P Dunn, and Yu Li, and Gabrielle Heilek, and Pete Dunten, and Todd R Elworthy, and Xiaochun Han, and Seth F Harris, and Donald R Hirschfeld, and J Heather Hogg, and Walter Huber, and Ann C Kaiser, and Denis J Kertesz, and Woongki Kim, and Taraneh Mirzadegan, and Michael G Roepel, and Y David Saito, and Tania M P C Silva, and Steven Swallow, and Jahari L Tracy, and Armando Villasenor, and Harit Vora, and Amy S Zhou, and Klaus Klumpp
August 2012, ACS medicinal chemistry letters,
Zachary K Sweeney, and James P Dunn, and Yu Li, and Gabrielle Heilek, and Pete Dunten, and Todd R Elworthy, and Xiaochun Han, and Seth F Harris, and Donald R Hirschfeld, and J Heather Hogg, and Walter Huber, and Ann C Kaiser, and Denis J Kertesz, and Woongki Kim, and Taraneh Mirzadegan, and Michael G Roepel, and Y David Saito, and Tania M P C Silva, and Steven Swallow, and Jahari L Tracy, and Armando Villasenor, and Harit Vora, and Amy S Zhou, and Klaus Klumpp
September 2009, Bioorganic & medicinal chemistry letters,
Zachary K Sweeney, and James P Dunn, and Yu Li, and Gabrielle Heilek, and Pete Dunten, and Todd R Elworthy, and Xiaochun Han, and Seth F Harris, and Donald R Hirschfeld, and J Heather Hogg, and Walter Huber, and Ann C Kaiser, and Denis J Kertesz, and Woongki Kim, and Taraneh Mirzadegan, and Michael G Roepel, and Y David Saito, and Tania M P C Silva, and Steven Swallow, and Jahari L Tracy, and Armando Villasenor, and Harit Vora, and Amy S Zhou, and Klaus Klumpp
February 2006, Current opinion in investigational drugs (London, England : 2000),
Zachary K Sweeney, and James P Dunn, and Yu Li, and Gabrielle Heilek, and Pete Dunten, and Todd R Elworthy, and Xiaochun Han, and Seth F Harris, and Donald R Hirschfeld, and J Heather Hogg, and Walter Huber, and Ann C Kaiser, and Denis J Kertesz, and Woongki Kim, and Taraneh Mirzadegan, and Michael G Roepel, and Y David Saito, and Tania M P C Silva, and Steven Swallow, and Jahari L Tracy, and Armando Villasenor, and Harit Vora, and Amy S Zhou, and Klaus Klumpp
December 2013, Future medicinal chemistry,
Zachary K Sweeney, and James P Dunn, and Yu Li, and Gabrielle Heilek, and Pete Dunten, and Todd R Elworthy, and Xiaochun Han, and Seth F Harris, and Donald R Hirschfeld, and J Heather Hogg, and Walter Huber, and Ann C Kaiser, and Denis J Kertesz, and Woongki Kim, and Taraneh Mirzadegan, and Michael G Roepel, and Y David Saito, and Tania M P C Silva, and Steven Swallow, and Jahari L Tracy, and Armando Villasenor, and Harit Vora, and Amy S Zhou, and Klaus Klumpp
September 2015, European journal of medicinal chemistry,
Copied contents to your clipboard!